Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database

Objective: The objective of this study was to scientifically and systematically explore the association between fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) and tendonitis and tendon rupture through the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: Disproportionality analysis was used to quantify the signals of fluoroquinolone-associated suspected tendonitis and tendon rupture based on the FAERS data from January 2016 to March 2021. Clinical characteristics, the onset time, oral and intravenous administrations, and the serious outcomes of fluoroquinolone-associated tendonitis and tendon rupture were further analyzed. Results: Out of 35,667 fluoroquinolone-associated adverse events recorded in the FAERS database during the study period, 1,771 tendonitis and 1,018 tendon ruptures induced by fluoroquinolones as the suspected drug were analyzed, with a median age of 49.88–63.87 years. All three fluoroquinolones detected positive signals of tendonitis and tendon rupture in the four methods. Ciprofloxacin had the strongest statistical association with tendonitis with the highest positive signal values (ROR 98.50, PRR 93.25, IC 6.15, and EBGM 76.80), while levofloxacin showed the strongest statistical association with tendon rupture (ROR 76.38, PRR 73.75, IC 5.84, and EBGM 63.89). Compared with ciprofloxacin and levofloxacin, moxifloxacin was relatively weakly associated with tendonitis and tendon rupture. Oral fluoroquinolone-induced tendonitis and tendon rupture had a stronger signal strength than intravenous administration. The majority of fluroquinolone-related suspected tendonitis and tendon rupture tended to occur within a few days or one month. As for the disability rate of tendonitis, ciprofloxacin counted the highest (n = 461, 50.94%), with moxifloxacin the lowest (n = 20, 29.41%). Conclusion: Fluoroquinolone-induced tendonitis and tendon rupture tended to occur early and might result in serious outcomes. Our study provided valuable references for early identification of the risk of fluoroquinolone-induced tendonitis and tendon rupture.

[1]  Chih-Chien Wang,et al.  Positive Association Between Fluoroquinolone Exposure and Tendon Disorders: A Nationwide Population-Based Cohort Study in Taiwan , 2022, Frontiers in Pharmacology.

[2]  Qilin Zhang,et al.  A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system , 2021, Expert opinion on drug safety.

[3]  N. Villagra,et al.  Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents , 2021, Molecules.

[4]  D. Leucuta,et al.  A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders , 2021, Scientific Reports.

[5]  C. McDonald,et al.  Association between tendon ruptures and use of fluoroquinolone, and other oral antibiotics: a 10-year retrospective study of 1 million US senior Medicare beneficiaries , 2020, BMJ Open.

[6]  Yingying Hu,et al.  Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. , 2020, International immunopharmacology.

[7]  F. Salvo,et al.  Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS) , 2020, Cancers.

[8]  C. Alves,et al.  Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis , 2019, European Journal of Clinical Pharmacology.

[9]  P. McGettigan,et al.  Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy. , 2019, JAMA neurology.

[10]  S. Jick,et al.  Clinical implications of the association between fluoroquinolones and tendon rupture: The magnitude of the effect with and without corticosteroids , 2019, British journal of clinical pharmacology.

[11]  Shusen Sun,et al.  Assessing fluoroquinolone‐associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system , 2019, International journal of clinical practice.

[12]  P. McGettigan,et al.  Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study , 2018, Clinical Drug Investigation.

[13]  Sparfloxacin , 2018, Reactions Weekly.

[14]  T. Lodise,et al.  Fluoroquinolone‐Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk? , 2016, Pharmacotherapy.

[15]  D. Redelmeier,et al.  Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study , 2015, BMJ Open.

[16]  C. Bennett,et al.  Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration’s adverse event reporting system , 2015, Expert opinion on drug safety.

[17]  L. Piddock,et al.  Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. , 2014, Trends in microbiology.

[18]  M. Lai,et al.  Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Hyon K. Choi,et al.  Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. , 2012, The American journal of medicine.

[20]  Muhammad M Mamdani,et al.  Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study , 2012, Canadian Medical Association Journal.

[21]  F. Kaleagasioglu,et al.  Fluoroquinolone-induced tendinopathy: etiology and preventive measures. , 2012, The Tohoku journal of experimental medicine.

[22]  FDA NEWS RELEASE , 2011 .

[23]  N. Niranjan,et al.  Management of bilateral Achilles tendon rupture associated with ciprofloxacin: a review and case presentation. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[24]  J. Hallas,et al.  Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study , 2007, European Journal of Clinical Pharmacology.

[25]  R. Owens,et al.  Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  L. Saravolatz,et al.  Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  B. Stricker,et al.  Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. , 2003, Archives of internal medicine.

[28]  G. Zhanel,et al.  Fluoroquinolone-associated tendinopathy: a critical review of the literature. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  P. Hawkey.  Mechanisms of quinolone action and microbial response. , 2003, Journal of Antimicrobial Chemotherapy.

[30]  B. Stricker,et al.  Fluoroquinolones and risk of Achilles tendon disorders: case-control study , 2002, BMJ : British Medical Journal.

[31]  K. Goa,et al.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. , 1997, Drugs.

[32]  N. Kounis,et al.  Kounis Syndrome After Intake of Levofloxacin: Increasing Incidence of Hypersensitivity to Fluoroquinolones. , 2017, Journal of investigational allergology & clinical immunology.

[33]  G. Corrao,et al.  Evidence of Tendinitis Provoked by Fluoroquinolone Treatment , 2006, Drug safety.

[34]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.